XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.

A
A

AstraZeneca

뉴스

Reuters - 4 시간 전

Astrazeneca Says Calquence Granted First Regulatory Approval In China For Adults With Previously Treated Mantle Cell Lymphoma

BRIEF-Astrazeneca Says Calquence Granted First Regulatory Approval In China For Adults With Previously Treated Mantle Cell Lymphoma March 23 (Reuters) - AstraZeneca PLC AZN.L : ASTRAZENECA - CALQUENCE GRANTED FIRST REGULATORY APPROVAL IN CHINA FOR ADULTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA Source text for Eikon: [ID:] Further company cover
A
Reuters - 5 시간 전

Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data

UPDATE 4-Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data Drug meets primary and all secondary goals in COPD trial Previous peak sales estimate of 13 bln euros was without COPD Drug could be first new COPD treatment in over a decade Adds share price performance, 2nd ongoing trial By Ludwig Burger and Juby Babu March 23 (Reuters) - Sanofi's SASY.PA asthma drug Dupixent met all targets in a trial to treat "smoker's lung", potentially adding billions to the French drugmaker's growth pros
A
R
S
Reuters - 1 주 전

How GSK plans to replenish its depleted medicine cabinet

FOCUS-How GSK plans to replenish its depleted medicine cabinet GSK has overhauled R&D dept since Walmsley became CEO Top scientist Wood says R&D dept now delivering results Wood says GSK now de-emphasizing oncology British peer Astra has strong oncology portfolio Investor concerns over GSK pipeline reflect in share price-analysts By Maggie Fick STEVENAGE, England, March 15 (Reuters) - GSK's GSK.L chief scientist says an overhaul of the drugmaker's R&D unit has begun delivering results - citing a
A
C
G
N
P
U
Reuters - 1 주 전

SVB shock could have chilling effect on British biotech sector

UPDATE 1-SVB shock could have chilling effect on British biotech sector UK deal averted disaster for biotech start-ups Some 40% of UK biotech firms were banking with SVB UK aims to be life sciences "superpower" Adds details about UK biotech that was exposed to SVB By Natalie Grover and Maggie Fick LONDON, March 13 (Reuters) - HSBC HSBA.L 's rescue of the British arm of Silicon Valley Bank saved the heavily-exposed UK biotech sector from collapse, but the fallout could hamper funding in a sector
A
B
G
H
Reuters - 1 주 전

SVB shock could have chilling effect on British biotech sector

SVB shock could have chilling effect on British biotech sector UK deal averted disaster for biotech start-ups Some 40% of UK biotech firms were banking with SVB UK aims to be life sciences "superpower" By Natalie Grover and Maggie Fick LONDON, March 13 (Reuters) - HSBC HSBA.L 's rescue of the British arm of Silicon Valley Bank saved the heavily-exposed UK biotech sector from collapse, but the fallout could hamper funding in a sector the government sees as key to future economic growth, industry
A
B
G
H
Reuters - 1 주 전

Pfizer snaps up Seagen for $43 bln as drugmaker extends buying spree

FACTBOX-Pfizer snaps up Seagen for $43 bln as drugmaker extends buying spree March 13 (Reuters) - Pfizer Inc PFE.N struck a $43 billion deal to buy Seagen Inc SGEN.O in the U.S. drugmaker's biggest in a string of acquisitions undertaken after a sales windfall from its COVID-19 products. The drugmaker has a history of transformative deals even before the pandemic such as spinning off its portfolio of off-patent drugs.
A
G
M
P
Reuters - 2 주 전

Imfinzi Significantly Improved Event-Free Survival In Aegean Phase Iii Trial For Patients With Resectable Non-Small Cell Lung Cancer

BRIEF-Imfinzi Significantly Improved Event-Free Survival In Aegean Phase Iii Trial For Patients With Resectable Non-Small Cell Lung Cancer March 9 (Reuters) - AstraZeneca PLC AZN.L : IMFINZI SIGNIFICANTLY IMPROVED EVENT-FREE SURVIVAL IN AEGEAN PHASE III TRIAL FOR PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER Source text for Eikon: ID:nBwlKlGG
A
Reuters - 2 주 전

AstraZeneca says Tagrisso Demonstrated Strong Overall Survival Benefit In Adaura Phase III Trial For Adjuvant Treatment Of Patients With Early-Stage Mutated Lung Cancer

BRIEF-AstraZeneca says Tagrisso Demonstrated Strong Overall Survival Benefit In Adaura Phase III Trial For Adjuvant Treatment Of Patients With Early-Stage EGFR-Mutated Lung Cancer March 9 (Reuters) - AstraZeneca PLC AZN.L : TAGRISSO® (OSIMERTINIB) DEMONSTRATED STRONG OVERALL SURVIVAL BENEFIT IN THE ADAURA PHASE III TRIAL FOR ADJUVANT TREATMENT OF
A
Reuters - 2 주 전

UK Stocks-Factors to watch on March 9

UPDATE 1-UK Stocks-Factors to watch on March 9 Adds news items, updates futures March 9 - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday with futures FFIc1 down 0.2 7 %. * SHELL: Shell's emissions dipped by about 10% in 2022 to a total of 1.232 billion tonnes of CO2 equivalent, from 1.367 billion tonnes the previous year, according to its annual report and Reuters calculations.
A
A
I
P
U
Reuters - 2 주 전

Astrazeneca Says Imfinzi Improved EFS In Resectable Lung Cancer

BRIEF-Astrazeneca Says Imfinzi Improved EFS In Resectable Lung Cancer March 9 (Reuters) - AstraZeneca PLC AZN.L : IMFINZI IMPROVED EFS IN RESECTABLE LUNG CANCER PHASE III TRIAL FOR PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER RESULTS SHOW IMFINZI-BASED TREATMENT BEFORE,AFTER SURGERY SIGNIFICANTLY INCREASE TIME PATIENTS LIVE WITHOUT RECURRENC
A
Reuters - 2 주 전

AstraZeneca says cancer drug Imfinzi improves survival chances in late-stage trial

UPDATE 1-AstraZeneca says cancer drug Imfinzi improves survival chances in late-stage trial Adds detail on trial, quote and background March 9 (Reuters) - Lung cancer patients treated with AstraZeneca's AZN.L immunotherapy Imfinzi pre- and post-surgery in a trial lived significantly longer without the disease progressing or recurring than those treated with chemotherapy, the drugmaker said on Thursday.
A
Reuters - 2 주 전

AstraZeneca says cancer drug Imfinzi improves survival rates in late-stage trial

AstraZeneca says cancer drug Imfinzi improves survival rates in late-stage trial March 9 (Reuters) - Drugmaker AstraZeneca AZN.L said on Thursday a late-stage trial showed that Imfinzi-based treatment before and after surgery significantly increased the time patients lived without the recurrence or progression of resectable lung cancer. Reporting b
A
Reuters - 2 주 전

Personalis Selected For Clinical Research After Successful Evaluation Of Whole Genome-Based Molecular Residual Disease Assay

BRIEF-Personalis Selected For Clinical Research After Successful Evaluation Of Whole Genome-Based Molecular Residual Disease Assay March 7 (Reuters) - Personalis Inc PSNL.O : PERSONALIS SELECTED FOR CLINICAL RESEARCH AFTER SUCCESSFUL EVALUATION OF WHOLE GENOME-BASED MOLECULAR RESIDUAL DISEASE ASSAY PERSONALIS INC - COMPANY WILL EXPLORE USE OF NEXT
A
Reuters - 2 주 전

UK stock indexes close down after Powell's hawkish remarks

UPDATE 2-UK stock indexes close down after Powell's hawkish remarks For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Premier Foods climbs on annual profit outlook raise Wood Group surges on plan to reject Apollo's latest buyout offer FTSE 100 down 0.1%, FTSE 250 off 0.5% Updates to market close By Johann M Cherian and Shristi Achar A March 7 (Reuters) - Britain's FTSE 100 closed down on Tuesday after hawkish comments from U.S.
A
A
E
G
H
W
U
Reuters - 2 주 전

AstraZeneca's Enhertu Showed Clinically Meaningful Responses Across Multiple Tumor Types In Phase II Trial

BRIEF-AstraZeneca's Enhertu Showed Clinically Meaningful Responses Across Multiple Tumor Types In Phase II Trial March 6 (Reuters) - AstraZeneca PLC AZN.L : ENHERTU® (FAM-TRASTUZUMAB DERUXTECAN-NXKI) SHOWED CLINICALLY MEANINGFUL AND DURABLE RESPONSES ACROSS MULTIPLE HER2-EXPRESSING TUMOR TYPES IN DESTINY-PANTUMOR02 PHASE II TRIAL ASTRAZENECA - AST
A
Reuters - 2 주 전

Miners drag FTSE 100 lower on China concerns

UPDATE 2-Miners drag FTSE 100 lower on China concerns For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Clarkson up on upbeat annual profit Rolls Royce gains on PT raise FTSE 100 down 0.2%, FTSE 250 adds 0.7% Updates to market close By Johann M Cherian and Shristi Achar A March 6 (Reuters) - The UK's blue-chip FTSE 100 fell on Monday as mining stocks slumped after top metals consumer China's decision to set a modest growth target, while a
A
C
F
U
Reuters - 2 주 전

UK Stocks-Factors to watch on March 6

UPDATE 1-UK Stocks-Factors to watch on March 6 Adds news items, updates futures March 6 - Britain's FTSE 100 .FTSE index is expected to dip at the open on Monday, with futures FFIc1 down 0.06%. * ASTRAZENECA : AstraZeneca AZN.L said a mid-stage trial of its cancer drug Enhertu showed positive results across multiple HER2-expressing advanced solid tumours in heavily pre-treated patients.
A
C
C
U
Reuters - 2 주 전

AstraZeneca cancer drug Enhertu show encouraging initial results for other tumours (March 6)

REFILE-AstraZeneca cancer drug Enhertu show encouraging initial results for other tumours (March 6) Refiles March 6 story to say that Daiichi Sankyo is a co-developer of Enhertu March 6 (Reuters) - AstraZeneca AZN.L said on Monday a mid-stage trial of its cancer drug Enhertu, co-developed with Daiichi Sankyo 4568.T , showed positive results across multiple HER2-expressing advanced solid tumours in heavily pre-treated patients.
A
Reuters - 2 주 전

Astrazeneca Says Enhertu Destiny-PanTumor02 Shows Positive Results

BRIEF-Astrazeneca Says Enhertu Destiny-PanTumor02 Shows Positive Results March 6 (Reuters) - AstraZeneca PLC AZN.L : ASTRAZENECA PLC - ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTS ASTRAZENECA PLC - ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTS ASTRAZENECA - ENHERTU SHOWED CLINICALLY MEANINGFUL AND DURABLE RESPONSES ACROSS MULTIPLE HER2-EXP
A
Reuters - 3 주 전

Viatris warns it will stop selling essential drugs in UK without changes to drug pricing agreement

Viatris warns it will stop selling essential drugs in UK without changes to drug pricing agreement By Maggie Fick and Natalie Grover LONDON, March 2 (Reuters) - Drugmaker Viatris Inc VTRS.O warned on Thursday that it will stop selling some essential medicines in the UK that are already in short supply unless the British government makes changes to its voluntary medicines pricing agreement.
A

조건

인기 자산

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

우리는 웹사이트에서 최고의 경험을 전해드리기 위해 쿠키를 사용하고 있습니다. 자세히 읽거나 쿠키 설정을 변경하세요.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.